Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Jaguar Health, Inc. issued 3,249,908 shares of warrant to Streeterville Capital, LLC for 99.3822 shares of Series L Preferred Stock.
- Security
- warrant
- Shares
- 3,249,908 shares
- Purchaser
- Streeterville Capital, LLC
- Consideration
- 99.3822 shares of Series L Preferred Stock
Exact text from the filing
pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 3,249,908 shares of Common Stock (the "Fourth Pre-Funded Warrant") to Streeterville in exchange for 99.3822 shares of Series L Preferred Stock held by Streeterville.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Jaguar Health, Inc. issued 719,424 shares of warrant to Iliad Research and Trading, L.P. for 22 shares of Series L Preferred Stock.
- Security
- warrant
- Shares
- 719,424 shares
- Purchaser
- Iliad Research and Trading, L.P.
- Consideration
- 22 shares of Series L Preferred Stock
Exact text from the filing
pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 719,424 shares of Common Stock (the "Third Pre-Funded Warrant") to Iliad in exchange for 22 shares of Series L Preferred Stock held by Iliad.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Jaguar Health, Inc. issued 1,553,844 shares of warrant to Iliad Research and Trading, L.P. for $1,187,914.07 reduction in the outstanding balance of the October 2020 Royalty Interest.
- Security
- warrant
- Shares
- 1,553,844 shares
- Purchaser
- Iliad Research and Trading, L.P.
- Consideration
- $1,187,914.07 reduction in the outstanding balance of the October 2020 Royalty Interest
Exact text from the filing
with Iliad. Pursuant to this agreement, the Company issued a pre-funded common stock purchase warrant to purchase 1,553,844 shares of Common Stock (the "First Pre-Funded Warrant") to Iliad in exchange for a $1,187,914.07 reduction in the outstanding balance of the October 2020 Royalty Interest.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Jaguar Health, Inc. issued 1,111,837 shares of warrant to Streeterville Capital, LLC for $850,000 reduction in the outstanding balance of the August 2022 Royalty Interest.
- Security
- warrant
- Shares
- 1,111,837 shares
- Purchaser
- Streeterville Capital, LLC
- Consideration
- $850,000 reduction in the outstanding balance of the August 2022 Royalty Interest
Exact text from the filing
with Streeterville. Pursuant to this agreement, the Company issued a pre-funded common stock purchase warrant to purchase 1,111,837 shares of Common Stock (the "Second Pre-Funded Warrant") to Streeterville in exchange for a $850,000 reduction in the outstanding balance of the August 2022 Royalty Interest.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Jaguar Health, Inc. issued 2,870,503 shares of warrant to Iliad Research and Trading, L.P. for 87.78 shares of Series M Preferred Stock.
- Security
- warrant
- Shares
- 2,870,503 shares
- Purchaser
- Iliad Research and Trading, L.P.
- Consideration
- 87.78 shares of Series M Preferred Stock
Exact text from the filing
pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 2,870,503 shares of Common Stock (the "Fifth Pre-Funded Warrant") to Iliad in exchange for 87.78 shares of Series M Preferred Stock held by Iliad.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Jaguar Health, Inc. entered into Streeterville Royalty Interest Exchange Agreement with Streeterville Capital, LLC valued at Issued a pre-funded common stock purchase warrant to purchase 1,111,837 shares of Common Stock in ex (effective 2026-01-16).
- Action
- entry
- Counterparty
- Streeterville Capital, LLC
- Value
- Issued a pre-funded common stock purchase warrant to purchase 1,111,837 shares of Common Stock in ex
- Effective
- 2026-01-16
Exact text from the filing
On January 16, 2026, the Company entered into a privately negotiated exchange agreement (the “Streeterville Royalty Interest Exchange Agreement”) with Streeterville.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Jaguar Health, Inc. entered into Streeterville Series L Exchange Agreement with Streeterville Capital, LLC valued at Issued a pre-funded common stock purchase warrant to purchase 3,249,908 shares of Common Stock in ex (effective 2026-01-16).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Streeterville Capital, LLC
- Value
- Issued a pre-funded common stock purchase warrant to purchase 3,249,908 shares of Common Stock in ex
- Effective
- 2026-01-16
Exact text from the filing
On January 16, 2026, the Company entered into a privately negotiated exchange agreement with Streeterville (the “Streeterville Series L Exchange Agreement”), pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 3,249,908 shares of Common Stock (the “Fourth Pre-Funded Warrant”) to Streeterville in exchange for 99.3822 shares of Series L Preferred Stock held by Streeterville.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Jaguar Health, Inc. entered into Streeterville Series M Exchange Agreement with Streeterville Capital, LLC valued at Issued a pre-funded common stock purchase warrant to purchase 2,270,765 shares of Common Stock in ex (effective 2026-01-16).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Streeterville Capital, LLC
- Value
- Issued a pre-funded common stock purchase warrant to purchase 2,270,765 shares of Common Stock in ex
- Effective
- 2026-01-16
Exact text from the filing
On January 16, 2026, the Company entered into a privately negotiated exchange agreement with Streeterville (the “Streeterville Series M Exchange Agreement”), pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 2,270,765 shares of Common Stock (the “Sixth Pre-Funded Warrant”) to Streeterville in exchange for 69.44 shares of Series M Preferred Stock held by Streeterville.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Jaguar Health, Inc. entered into Iliad Series M Exchange Agreement with Iliad Research and Trading, L.P. valued at Issued a pre-funded common stock purchase warrant to purchase 2,870,503 shares of Common Stock in ex (effective 2026-01-16).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Iliad Research and Trading, L.P.
- Value
- Issued a pre-funded common stock purchase warrant to purchase 2,870,503 shares of Common Stock in ex
- Effective
- 2026-01-16
Exact text from the filing
On January 16, 2026, the Company entered into a privately negotiated exchange agreement with Iliad (the “Iliad Series M Exchange Agreement”), pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 2,870,503 shares of Common Stock (the “Fifth Pre-Funded Warrant”) to Iliad in exchange for 87.78 shares of Series M Preferred Stock held by Iliad.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Jaguar Health, Inc. entered into Iliad Royalty Interest Exchange Agreement with Iliad Research and Trading, L.P. valued at Issued a pre-funded common stock purchase warrant to purchase 1,553,844 shares of Common Stock in ex (effective 2026-01-16).
- Action
- entry
- Counterparty
- Iliad Research and Trading, L.P.
- Value
- Issued a pre-funded common stock purchase warrant to purchase 1,553,844 shares of Common Stock in ex
- Effective
- 2026-01-16
Exact text from the filing
On January 16, 2026, the Company entered into a privately negotiated exchange agreement (the “Iliad Royalty Interest Exchange Agreement”) with Iliad.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Jaguar Health, Inc. entered into Iliad Series L Exchange Agreement with Iliad Research and Trading, L.P. valued at Issued a pre-funded common stock purchase warrant to purchase 719,424 shares of Common Stock in exch (effective 2026-01-16).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Iliad Research and Trading, L.P.
- Value
- Issued a pre-funded common stock purchase warrant to purchase 719,424 shares of Common Stock in exch
- Effective
- 2026-01-16
Exact text from the filing
On January 16, 2026, the Company entered into a privately negotiated exchange agreement with Iliad (the “Iliad Series L Exchange Agreement”), pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 719,424 shares of Common Stock (the “Third Pre-Funded Warrant”) to Iliad in exchange for 22 shares of Series L Preferred Stock held by Iliad.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.